Neil Berkley
Vermögen: 820 584 $ am 31.05.2026
Vermögen: 820 584 $ am 31.05.2026
Neil L.
Berkley is the founder of MPEX Pharmaceuticals, Inc., founded in 2001, and Vaxiion Therapeutics LLC, founded in 2000.
Current jobs include Director at Navigen, Inc., and Chief Financial & Business Officer at Alector, Inc. starting in 2025.
Former jobs include Independent Non-Executive Director at ProLung, Inc. in 2018; Chief Business Officer at AbCellera Biologics, Inc. from 2021 to 2022; Vice President & Head-Business Development at Halozyme Therapeutics, Inc. from 2019 to 2021; Chief Corporate Development Officer at Juvena Therapeutics, Inc. from 2022 to 2024; and Head-Business Development at Cadence Pharmaceuticals, Inc. from 2011 to 2014.
Education includes graduate and MBA degrees from San Diego State University and an undergraduate degree from the University of California San Diego.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ALECTOR, INC. 0,34 % | 02.06.2026 | 379.900 ( 0,34 % ) | 820 584 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ALECTOR, INC. | Finanzdirektor/CFO | 20.06.2025 |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics treatment and platform for myopathies and metabolic diseases | Corporate Officer/Principal | 01.04.2024 |
| ABCELLERA BIOLOGICS INC. | Corporate Officer/Principal | 29.06.2022 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2021 |
| PROLUNG, INC. | Direktor/Vorstandsmitglied | 27.06.2018 |
Cadence Pharmaceuticals , Inc. | Corporate Officer/Principal | 01.05.2014 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
ProLung, Inc.
ProLung, Inc. Medical SpecialtiesHealth Technology Develops screening technology for early detection of cancer | Health Technology |
San Diego State University
San Diego State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops therapies for antibiotic resistance | Commercial Services |
Vaxiion Therapeutics, Inc.
Vaxiion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Health Technology |
Alector, Inc.
Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
AbCellera Biologics, Inc.
AbCellera Biologics, Inc. BiotechnologyHealth Technology Discovers and develops antibody drugs & therapeutics | Health Technology |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics treatment and platform for myopathies and metabolic diseases | Health Technology |
Cadence Pharmaceuticals , Inc. | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen